rs754609778
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000198.4(HSD3B2):βc.818_819delβ(p.Lys273ArgfsTer7) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000889 in 1,461,840 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ).
Frequency
Genomes: not found (cov: 31)
Exomes π: 0.0000089 ( 0 hom. )
Consequence
HSD3B2
NM_000198.4 frameshift
NM_000198.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.26
Genes affected
HSD3B2 (HGNC:5218): (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2) The protein encoded by this gene is a bifunctional enzyme that catalyzes the oxidative conversion of delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. It plays a crucial role in the biosynthesis of all classes of hormonal steroids. This gene is predominantly expressed in the adrenals and the gonads. Mutations in this gene are associated with 3-beta-hydroxysteroid dehydrogenase, type II, deficiency. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Oct 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 6 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-119422317-CAA-C is Pathogenic according to our data. Variant chr1-119422317-CAA-C is described in ClinVar as [Pathogenic]. Clinvar id is 586031.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HSD3B2 | NM_000198.4 | c.818_819del | p.Lys273ArgfsTer7 | frameshift_variant | 4/4 | ENST00000369416.4 | NP_000189.1 | |
HSD3B2 | NM_001166120.2 | c.818_819del | p.Lys273ArgfsTer7 | frameshift_variant | 4/4 | NP_001159592.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HSD3B2 | ENST00000369416.4 | c.818_819del | p.Lys273ArgfsTer7 | frameshift_variant | 4/4 | 1 | NM_000198.4 | ENSP00000358424 | P1 | |
HSD3B2 | ENST00000543831.5 | c.818_819del | p.Lys273ArgfsTer7 | frameshift_variant | 4/4 | 3 | ENSP00000445122 | P1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 genomes
Cov.:
31
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251282Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135810
GnomAD3 exomes
AF:
AC:
8
AN:
251282
Hom.:
AF XY:
AC XY:
7
AN XY:
135810
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000889 AC: 13AN: 1461840Hom.: 0 AF XY: 0.0000138 AC XY: 10AN XY: 727226
GnomAD4 exome
AF:
AC:
13
AN:
1461840
Hom.:
AF XY:
AC XY:
10
AN XY:
727226
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 31
GnomAD4 genome
Cov.:
31
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 27, 2023 | This sequence change creates a premature translational stop signal (p.Lys273Argfs*7) in the HSD3B2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 100 amino acid(s) of the HSD3B2 protein. This variant is present in population databases (rs754609778, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with 3-beta-hydroxysteroid dehydrogenase deficiency (PMID: 8004103). This variant is also known as 273deltaAA. ClinVar contains an entry for this variant (Variation ID: 586031). This variant disrupts a region of the HSD3B2 protein in which other variant(s) (p.Arg335*) have been determined to be pathogenic (PMID: 18252794, 31006099). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Sep 15, 2017 | - - |
3 beta-Hydroxysteroid dehydrogenase deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Biochemistry Laboratory, Health Services Laboratory | Nov 20, 2023 | ACMG:PVS1 PM2 PP3 PP4 - |
Congenital adrenal hyperplasia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 15, 2022 | Variant summary: HSD3B2 c.818_819delAA (p.Lys273ArgfsX7) results in a premature termination codon, which is predicted to cause a truncation of the encoded protein. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 3.2e-05 in 251282 control chromosomes (gnomAD). c.818_819delAA has been reported in the literature in multiple individuals affected with Congenital Adrenal Hyperplasia (e.g. Chang_1995, Simard_1994, Marui_2000, Leka-Emiri_2022). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters have assessed the variant since 2014: both classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at